This site is intended for health professionals only!
Arpida (SWX: ARPN) have announced that the US Food and Drug Administration (FDA) has posted on its website briefing documents for the November 20, 2008 Anti-Infective Drugs Advisory Committee (AIDAC) meeting.
The AIDAC will discuss and review Arpida’s New Drug Application for iclaprim for the treatment of complicated skin and skin structure infection (cSSSI) caused by gram-positive organisms, including methicillin-resistant Staphylococcus aureus, or MRSA.
Iclaprim is an antibiotic currently in development for the treatment of serious infections requiring hospitalisation caused by gram-positive bacteria, including those caused by MRSA.
Iclaprim was developed to meet a growing medical need for additional treatment options to combat resistant infections and is the first antibiotic in the dihydrofolate reductase (DHFR) selective inhibitor class to demonstrate efficacy against cSSSIs caused by MRSA. The DHFR class has been proven safe and effective in more than four decades of clinical use.